Adverum Biotechnologies, Inc.
$4.36
+0.0000%Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -0.7).
Valuation inputs: P/E -0.7, earnings yield N/A, momentum 0.0%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -1.9%, ROIC -94.2%).
Profitability stack: net margin -130.9%, ROE -1.9%, ROIC -94.2%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +60.7%, momentum 0.0%, net margin -130.9%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Adverum Biotechnologies, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Adverum Biotechnologies, Inc. Fair Value Envelope
Adverum Biotechnologies, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Adverum Biotechnologies, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Adverum Biotechnologies, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.
Working Capital
Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.
Asset Composition
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
Adverum Biotechnologies, Inc. Street Expectations Map
Wall Street analysts project that ADVM stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 4.83, with estimates ranging from a low of 4.00 to a high of 5.50.
The consensus 1-year price target stands at 4.83, with estimates ranging from a low of 4.00 to a high of 5.50.
Analyst Consensus Analysis
Upside Potential
Moderate upside. Analysts expect positive returns but with limited margin of safety. Consider entry timing.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Risk-Reward Profile
Favorable risk-reward. Potential upside significantly exceeds downside risk, offering asymmetric return profile attractive for risk-tolerant investors.
Analyst Conviction
Positive outlook with reasonable agreement. Analysts generally optimistic about prospects with manageable uncertainty.
Market Sentiment Insight
Asymmetric upside: Strong return potential with favorable risk-reward profile. The limited downside relative to upside makes this an attractive risk-adjusted opportunity for growth-oriented portfolios.
Adverum Biotechnologies, Inc. Insider Positioning
During the last 12 months, insiders have purchased $966K and sold $18.21M worth of ADVM shares, resulting in $17.24M of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
117.6K
506.92K
0
0.00
+507K
+$507K
6-9 Months
61.1K
258.00K
1.1M
4.61M
-4.4M
-$4.35M
9-12 Months
86.7K
201.24K
199.5K
13.60M
-13.4M
-$13.40M
Top Buyers
Fischer Laurent
Director, Officer: Ceo, President And Director
$554K
Soparkar Peter
Officer: Chief Operating Officer
$211K
Hong Soo
Director
$24K
Nicholson, C. David
Director
$24K
Whitcup Scott M
Director
$24K
Top Sellers
Fischer Laurent
Director, Officer: Ceo, President And Director
$9.14M
Leonard Braden Michael
10 Percent Owner
$4.61M
Soparkar Peter
Officer: Chief Operating Officer
$2.75M
Seyedkazemi Setareh
Officer: Chief Development Officer
$906K
Rubinstein Linda M
Officer: Chief Financial Officer
$697K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $17.24M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
No Dividend Yield Data
ADVM has not reported any dividend yield values in the available annual periods.
advm Dividend History
Learning Layer
Related Guides
Build conviction on ADVM by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.